Skip to main content

Research Repository

Advanced Search

Oncology Activity

Gill, Jason H.; Shnyder, Steven D.

Authors

Jason H. Gill

Steven D. Shnyder



Contributors

Franz J. Hock
Editor

Abstract

The development of therapeutics to treat cancer is conceptually more difficult than for nonlife-threatening diseases for several reasons, including its complex pathophysiological nature, the molecular individuality of each tumor, and the robustness and predictability of preclinical models toward determining efficacy and safety. A major limitation to development of a “blockbuster” therapeutic strategy is the infinite combination of cellular and molecular perturbations and associated heterogeneity of causative genetic factors driving disease progression. Although challenging, the diversity of drug targets, coupled with the lethality of the disease, has encouraged studies of a vast array of approaches and opportunities for disease treatment over the years.

Citation

Gill, J. H., & Shnyder, S. D. (2016). Oncology Activity. In F. J. Hock (Ed.), Drug discovery and evaluation : pharmacological assays (4157-4200). (4th ed.). Springer Verlag. https://doi.org/10.1007/978-3-319-05392-9_113

Acceptance Date Dec 21, 2015
Publication Date Jan 1, 2016
Deposit Date Dec 21, 2015
Publicly Available Date Mar 28, 2024
Publisher Springer Verlag
Pages 4157-4200
Series Title Springer reference
Edition 4th ed.
Book Title Drug discovery and evaluation : pharmacological assays.
ISBN 9783319053912
DOI https://doi.org/10.1007/978-3-319-05392-9_113